[go: up one dir, main page]

IN2014DN00101A - - Google Patents

Info

Publication number
IN2014DN00101A
IN2014DN00101A IN101DEN2014A IN2014DN00101A IN 2014DN00101 A IN2014DN00101 A IN 2014DN00101A IN 101DEN2014 A IN101DEN2014 A IN 101DEN2014A IN 2014DN00101 A IN2014DN00101 A IN 2014DN00101A
Authority
IN
India
Prior art keywords
dendrimer
macromolecules
pharmaceutically active
active agent
surface amino
Prior art date
Application number
Other languages
English (en)
Inventor
David Owen
Brian Devlin Kelly
Peter Karellas
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Publication of IN2014DN00101A publication Critical patent/IN2014DN00101A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Bipolar Transistors (AREA)
IN101DEN2014 2011-06-06 2012-06-06 IN2014DN00101A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493886P 2011-06-06 2011-06-06
PCT/AU2012/000647 WO2012167309A1 (fr) 2011-06-06 2012-06-06 Macromolécules

Publications (1)

Publication Number Publication Date
IN2014DN00101A true IN2014DN00101A (fr) 2015-05-15

Family

ID=47295262

Family Applications (1)

Application Number Title Priority Date Filing Date
IN101DEN2014 IN2014DN00101A (fr) 2011-06-06 2012-06-06

Country Status (18)

Country Link
US (2) US9744246B2 (fr)
EP (1) EP2729179B1 (fr)
JP (1) JP6158177B2 (fr)
KR (1) KR101941318B1 (fr)
CN (2) CN103796684B (fr)
AU (1) AU2012267200B2 (fr)
BR (1) BR112013031556B1 (fr)
CA (1) CA2837979C (fr)
DK (1) DK2729179T3 (fr)
ES (1) ES2834992T3 (fr)
HR (1) HRP20201998T1 (fr)
HU (1) HUE052285T2 (fr)
IN (1) IN2014DN00101A (fr)
LT (1) LT2729179T (fr)
PL (1) PL2729179T3 (fr)
PT (1) PT2729179T (fr)
SI (1) SI2729179T1 (fr)
WO (1) WO2012167309A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117164357A (zh) * 2023-01-03 2023-12-05 广东捷成科创电子股份有限公司 一种五元系大功率型压电陶瓷材料及其制备方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
EP2996726A1 (fr) * 2013-05-16 2016-03-23 Université de Strasbourg Composés dendritiques comprenant un agent chélatant, fluorochrome ou agent de reconnaissance, compositions les comprenant et leurs utilisations
US20160220689A1 (en) * 2013-09-10 2016-08-04 Starpharma Pty Ltd. Macromolecules of dendrimer-platinum conjugates
WO2015184510A1 (fr) 2014-06-06 2015-12-10 Starpharma Pty Ltd Conjugués de type dendrimère-médicament
MX381031B (es) 2015-08-11 2025-03-12 Coherent Biopharma | Ltd Conjugados fármaco-multiligando y usos de los mismos.
CN106554329B (zh) * 2015-09-26 2019-07-05 南京友怡医药科技有限公司 水溶性紫杉醇抗癌药物化合物及其制备方法和应用
CN106554330B (zh) * 2015-09-26 2019-07-05 南京友怡医药科技有限公司 水溶性多西他赛抗癌药物化合物及其制备方法和应用
WO2017068051A1 (fr) * 2015-10-21 2017-04-27 Lek Pharmaceuticals D.D. Dendron à base de peg et son procédé de production
WO2017135893A1 (fr) * 2016-02-05 2017-08-10 Nipsea Technologies Pte Ltd Revêtements aqueux à base d'amines dendritiques
WO2017196986A1 (fr) * 2016-05-10 2017-11-16 Massachusetts Institute Of Technology Conjugués dendrimère-médicament, compositions de type hydrogel, et méthodes
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
WO2019189853A1 (fr) * 2018-03-29 2019-10-03 日油株式会社 Conjugué de polyéthylène glycol dégradable
MX2021000677A (es) 2018-07-19 2021-03-25 Starpharma Pty Ltd Dendrimero terapeutico.
US12071517B2 (en) 2018-07-19 2024-08-27 Starpharma Pty Ltd. Therapeutic dendrimer
TWI856967B (zh) * 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
CA3119993A1 (fr) * 2018-11-20 2020-05-28 Starpharma Pty Ltd Dendrimere therapeutique
EP3886912A4 (fr) * 2018-11-29 2023-01-04 Starpharma Pty Limited Dendrimère pour thérapie et imagerie
AU2020338481A1 (en) * 2019-08-28 2022-03-03 Starpharma Pty Ltd Targeted dendrimer conjugates
AU2020354787A1 (en) * 2019-09-26 2022-04-14 Starpharma Pty Ltd Therapeutic dendrimer
TW202206106A (zh) * 2020-04-24 2022-02-16 大陸商上海森輝醫藥有限公司 一類載藥的大分子及其製備方法
CN115989039A (zh) * 2020-06-03 2023-04-18 星药私人有限公司 治疗缀合物
EP4205767A4 (fr) * 2020-08-25 2024-04-10 Shanghai Senhui Medicine Co., Ltd. Macromolécule chargée en médicament et sa méthode de préparation
US20230263900A1 (en) * 2020-08-31 2023-08-24 Starpharma Pty Ltd. Dendrimer-drug conjugate
WO2022066891A1 (fr) * 2020-09-24 2022-03-31 Ocular Therapeutix, Inc. Inserts intracanaliculaires biodégradables à libération prolongée comprenant un hydrogel et un agent actif
BR112023004378A2 (pt) * 2020-09-24 2023-04-04 Ocular Therapeutix Inc Insertos intracanaliculares biodegradáveis de liberação sustentada que compreendem um hidrogel e uma ciclosporina
CN121079342A (zh) * 2023-05-08 2025-12-05 上海森辉医药有限公司 抗真菌药的载药大分子及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
CN101102787A (zh) * 2004-08-09 2008-01-09 艾丽奥斯生物制药有限公司 合成的超糖基化、抗蛋白酶的多肽变体、口服制剂及其使用方法
CN104524596B (zh) * 2006-01-20 2018-10-09 星药股份有限公司 经修饰的大分子
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
US8420067B2 (en) * 2006-08-11 2013-04-16 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
US8680315B2 (en) 2008-06-26 2014-03-25 Prolynx, Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
WO2011072290A2 (fr) * 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Conjugués de médicament dendrimère ciblés
US8754190B2 (en) 2010-05-05 2014-06-17 Prolynx Llc Controlled release from macromolecular conjugates
EP2566334B1 (fr) 2010-05-05 2018-04-18 Prolynx, LLC Supports solides pour la libération contrôlée de médicaments
EP2571496A4 (fr) 2010-05-05 2016-03-30 Prolynx Llc Libération contrôlée de médicament à partir de dendrimères

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117164357A (zh) * 2023-01-03 2023-12-05 广东捷成科创电子股份有限公司 一种五元系大功率型压电陶瓷材料及其制备方法

Also Published As

Publication number Publication date
JP6158177B2 (ja) 2017-07-05
CN110124051A (zh) 2019-08-16
CA2837979C (fr) 2021-03-30
US20170354739A1 (en) 2017-12-14
JP2014520105A (ja) 2014-08-21
AU2012267200B2 (en) 2016-02-25
US9744246B2 (en) 2017-08-29
ES2834992T3 (es) 2021-06-21
CN103796684A (zh) 2014-05-14
EP2729179A1 (fr) 2014-05-14
DK2729179T3 (da) 2020-12-21
KR20140041678A (ko) 2014-04-04
EP2729179A4 (fr) 2015-01-28
HRP20201998T1 (hr) 2021-02-05
EP2729179B1 (fr) 2020-09-23
WO2012167309A1 (fr) 2012-12-13
BR112013031556A2 (fr) 2017-08-29
KR101941318B1 (ko) 2019-01-22
US20140171375A1 (en) 2014-06-19
BR112013031556B1 (pt) 2022-03-29
HK1198356A1 (en) 2015-04-10
CN103796684B (zh) 2019-06-25
LT2729179T (lt) 2020-12-28
PL2729179T3 (pl) 2021-07-19
CA2837979A1 (fr) 2012-12-13
SI2729179T1 (sl) 2021-01-29
PT2729179T (pt) 2020-11-25
CN110124051B (zh) 2022-10-21
HUE052285T2 (hu) 2021-04-28
AU2012267200A1 (en) 2013-05-09
US10265409B2 (en) 2019-04-23

Similar Documents

Publication Publication Date Title
IN2014DN00101A (fr)
MX2019000566A (es) Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña.
MX370543B (es) Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
PH12013500257A1 (en) Prodrugs comprising an exendin linker conjugate
WO2014205317A3 (fr) Peptides cycliques utilisés en tant qu'agents de ciblage de protéines
WO2011130615A3 (fr) Synthèse de lacosamide
MX2013001677A (es) Formulaciones estables de linaclotida.
WO2012075086A3 (fr) Composition de soin d'étoffes
EP4253395A3 (fr) Procédés de préparation d'agents arn conjugués à des carbohydrates
SG194175A1 (en) Polymer conjugated prostaglandin analogues
WO2013019658A3 (fr) Nanosupports synthétiques comprenant des polymères comprenant de multiples agents immunomodulateurs
PH12012502452A1 (en) Vectors and sequences for the treatment of diseases
HK1198629A1 (en) High-loading water-soluble carrier-linked prodrugs
WO2016004048A3 (fr) Conjugués ciblés, particules et préparations associées
IN2012DN02736A (fr)
WO2013040242A3 (fr) Compositions de comblement dermique pour le traitement des ridules
WO2012174158A3 (fr) Administration de benzodiazépine
EP4414376A3 (fr) Nouveau depsipeptide et ses utilisations
IN2014DN08299A (fr)
MX2014004196A (es) Citramida de rasagilina.
EP2574170A4 (fr) Compositions immunostimulatrices et vaccinales
GEP20166450B (en) Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
MX2021005756A (es) Dendrimero terapeutico.
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
WO2012053013A3 (fr) Compositions pharmaceutiques d'agents anti-acné